Fennec Pharmaceuticals Stock Analysis

FENC Stock  USD 4.72  0.08  1.72%   
Fennec Pharmaceuticals is undervalued with Real Value of 7.46 and Target Price of 16.17. The main objective of Fennec Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Fennec Pharmaceuticals is worth, separate from its market price. There are two main types of Fennec Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Fennec Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Fennec Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.

Fennec Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.04. Fennec Pharmaceuticals had not issued any dividends in recent years. The entity had 1:3 split on the 5th of September 2014. Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Fennec Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about Fennec Pharmaceuticals call Rostislav Raykov at 919 636 4530 or check out https://www.fennecpharma.com.

Fennec Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fennec Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fennec Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Fennec Pharmaceuticals generated a negative expected return over the last 90 days
Fennec Pharmaceuticals has high historical volatility and very poor performance
Fennec Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 21.25 M. Net Loss for the year was (16.05 M) with profit before overhead, payroll, taxes, and interest of 1.45 M.
Fennec Pharmaceuticals currently holds about 14.91 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57.
Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 16.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3

Fennec Pharmaceuticals Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fennec Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Fennec Largest EPS Surprises

Earnings surprises can significantly impact Fennec Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-05-09
2019-03-31-0.15-0.130.0213 
2020-08-05
2020-06-30-0.18-0.21-0.0316 
2018-08-13
2018-06-30-0.11-0.14-0.0327 
View All Earnings Estimates

Fennec Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Fennec Pharmaceuticals' ESG score is a quantitative measure that evaluates Fennec Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Fennec Pharmaceuticals' operations that may have significant financial implications and affect Fennec Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Fennec Stock Institutional Investors

Shares
Morgan Stanley - Brokerage Accounts2024-06-30
204.2 K
Northern Trust Corp2024-09-30
139.7 K
Winton Capital Group Ltd2024-09-30
71.7 K
Millennium Management Llc2024-06-30
69.3 K
Bank Of New York Mellon Corp2024-06-30
68.7 K
Cibc World Markets Inc.2024-06-30
56.9 K
Charles Schwab Investment Management Inc2024-09-30
55.5 K
Acadian Asset Management Llc2024-06-30
53.3 K
Advantage Alpha Capital Partners, Lp2024-09-30
52.9 K
Southpoint Capital Advisors Lp2024-06-30
4.1 M
Sonic Gp Llc2024-09-30
2.4 M
Note, although Fennec Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Fennec Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 129.48 M.

Fennec Profitablity

The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.75) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.75.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.60)(0.63)
Return On Capital Employed(0.66)(0.63)
Return On Assets(0.60)(0.63)
Return On Equity 1.38  1.45 

Management Efficiency

Fennec Pharmaceuticals has return on total asset (ROA) of 0.027 % which means that it generated a profit of $0.027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.45, whereas Return On Tangible Assets are forecasted to decline to (0.63). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 1.21, whereas Total Assets are forecasted to decline to about 16.1 M.
Last ReportedProjected for Next Year
Book Value Per Share(0.44)(0.42)
Tangible Book Value Per Share(0.44)(0.42)
Enterprise Value Over EBITDA(25.55)(26.82)
Price Book Value Ratio(25.65)(24.37)
Enterprise Value Multiple(25.55)(26.82)
Price Fair Value(25.65)(24.37)
Enterprise Value88.5 M92.9 M
Leadership effectiveness at Fennec Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin
(0.75)
Profit Margin
(0.02)
Beta
0.267
Return On Assets
0.027
Return On Equity
(10.06)

Technical Drivers

As of the 22nd of November, Fennec Pharmaceuticals shows the Mean Deviation of 2.93, standard deviation of 3.96, and Variance of 15.67. Fennec Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Fennec Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Fennec Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Fennec Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Fennec Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fennec Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fennec Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fennec Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Hackman Jeffrey S. a day ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. 2 days ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. 3 days ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Robert Andrade few days ago
Acquisition by Robert Andrade of 15816 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3
 
Hackman Jeffrey S. few days ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. few days ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. six days ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. over a week ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Sayad Pierre Sargis over a week ago
Acquisition by Sayad Pierre Sargis of 150000 shares of Fennec Pharmaceuticals at 4.23 subject to Rule 16b-3
 
Hackman Jeffrey S. over a week ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. over two weeks ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3
 
Hackman Jeffrey S. over two weeks ago
Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3

Fennec Pharmaceuticals Outstanding Bonds

Fennec Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fennec Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fennec bonds can be classified according to their maturity, which is the date when Fennec Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Fennec Pharmaceuticals Predictive Daily Indicators

Fennec Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fennec Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Fennec Pharmaceuticals Corporate Filings

F4
18th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
14th of November 2024
Other Reports
ViewVerify
F4
13th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
10Q
8th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
F3
4th of November 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
8K
30th of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
10th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Fennec Pharmaceuticals Forecast Models

Fennec Pharmaceuticals' time-series forecasting models are one of many Fennec Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fennec Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Fennec Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Fennec Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fennec shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fennec Pharmaceuticals. By using and applying Fennec Stock analysis, traders can create a robust methodology for identifying Fennec entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.75)(0.79)
Operating Profit Margin(0.60)(0.63)
Net Loss(0.75)(0.79)
Gross Profit Margin 0.94  0.89 

Current Fennec Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fennec analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fennec analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
16.17Strong Buy4Odds
Fennec Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Fennec analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Fennec stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Fennec Pharmaceuticals, talking to its executives and customers, or listening to Fennec conference calls.
Fennec Analyst Advice Details

Fennec Stock Analysis Indicators

Fennec Pharmaceuticals stock analysis indicators help investors evaluate how Fennec Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Fennec Pharmaceuticals shares will generate the highest return on investment. By understating and applying Fennec Pharmaceuticals stock analysis, traders can identify Fennec Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow23.8 M
Long Term Debt30.9 M
Common Stock Shares Outstanding26.6 M
Total Stockholder Equity-11.6 M
Cash And Short Term Investments13.3 M
Cash13.3 M
Accounts Payable3.8 M
Net Debt17.7 M
50 Day M A4.668
Total Current Liabilities7.6 M
Other Operating Expenses34 M
Non Current Assets Total6000.00
Forward Price Earnings238.0952
Non Currrent Assets Other6000.00
Stock Based Compensation5.4 M

Complementary Tools for Fennec Stock analysis

When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
CEOs Directory
Screen CEOs from public companies around the world